In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AutoCyte, NeoPath merge in $101mm stock swap

Executive Summary

Yielding what industry analysts deem to be around a 50% share of the US Pap smear market, cervical cell screening technology company AutoCyte will acquire automated Pap smear developer NeoPath in a stock swap valued at about $101mm, based on AutoCyte's $7.35 pre-announcement 10-day average trailing price. The price represents a (pr)46% premium to the $3.97 10-day trailing average for NeoPath common.
Deal Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Cytology
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock

Related Companies